Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Agnes MattssonSandra Eketorp SylvanPer AxelssonFredrik EllinChristian KjellanderKarin LarssonBirgitta LauriCatharina LewerinChristian ScharenbergLove TättingHemming JohanssonAnders ÖsterborgLotta HanssonPublished in: European journal of haematology (2023)
Our real-world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced-stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double-refractory to inhibitors of BTK and Bcl-2.